한글목차

세계의 항악성종양제 시장은 2019년에 918억 1,197만 달러로 평가되었고 2024년까지 연평균 복합 성장률(CAGR) 7.00% 이상을 나타낼 전망입니다.

생물 제제 개발 증가

생물 제제 개발 증가는 실적 기간 동안 항신 생물 제의 성장을 가속했습니다. 항악성종양제는 생물제제의 개발을 촉진하고 암 치료의 기초가 되는 이해를 제공하는 데 도움이 됩니다. 항악성종양제는 단일클론 항체 및 면역관문억제제를 포함한 표적 생물학적 제제의 통합을 촉진하여 보다 정확하고 효과적인 치료 및 부작용을 감소시킵니다. 종양 생물학과 치료 경로에 대한 귀중한 인사이트력을 제공함으로써 이러한 약물은 생물학적 요법의 혁신을 가속화합니다. 예를 들어 미국에 본사를 둔 산업 단체인 미국 연구 제약 공업 협회(PhRMA)에 따르면 2022년 말까지 40개 바이오시밀러가 승인을 받았으며 그 중 27개는 미국에서 판매되고 있습니다. 이에 따라 생물제제 개발 증가가 항악성종양제 시장 성장을 견인했습니다.

목차

제1장 주요 요약

• 항악성종양제 - 시장 매력과 거시경제 상황

제2장 목차

제3장 표 일람

제4장 그림 일람

제5장 보고서 구성

제6장 시장 특징

• 일반적인 시장 정의
• 개요
• 항악성종양제 시장 정의와 세분화
• 유형별 시장 세분화
  • 알킬화제
  • 항대사제
  • 호르몬 및 길항제
  • 기타
• 질병 유형별 시장 세분화
  • 위장 암
  • 전립선 암
  • 폐암
  • 유방암
  • 기타 질환 유형
• 최종 사용자별 시장 세분화
  • 병원
  • 클리닉
  • 암 재활센터
  • 외래수술센터(ASC)
  • 기타

제7장 주요 시장 동향

• 정밀의료에 의한 암 치료의 진보
• 표적 요법에 의한 치료 정밀도의 향상
• 정밀 종양학 접근법에 의한 독성 최소화
• 시그널 경로 저해에 의한 암 치료 성적의 향상

제8장 항악성종양제 성장 분석과 전략 분석 프레임워크

• 세계의 항악성종양제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인)
  • 정치
  • 경제
  • 사회
  • 기술
  • 환경
  • 법률
• 최종 사용자 분석
  • 병원
  • 클리닉
  • 암 재활센터
  • 외래수술센터(ASC)
• 항악성종양제 시장 : 성장률 분석
• 시장 성장 실적(2019-2024년)
  • 시장 성장 촉진요인(2019-2024년)
  • 시장 성장 억제요인(2019-2024년)
• 시장 성장 예측(2024-2029년, 2034년)
• 성장 예측의 공헌 요인
  • 양적 성장의 공헌 요인
  • 성장 촉진요인
  • 성장 억제요인
• 항악성종양제 : 전체 시장(TAM)

제9장 항악성종양제 시장 : 세분화

• 항악성종양제 시장 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 항악성종양제 시장 : 질환 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 항악성종양제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 항악성종양제 시장 : 알킬화제 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 항악성종양제 시장 : 항대사제 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 항악성종양제 시장 : 호르몬 및 길항제 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 항악성종양제 시장 : 기타 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)

제10장 항악성종양제 시장 : 지역·국가별 분석

• 항악성종양제 시장 : 지역별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 항악성종양제 시장 : 국가별, 분석과 예측(2019-2024년, 2029년, 2034년)

제11장 아시아태평양 시장

제12장 서유럽 시장

제13장 동유럽 시장

제14장 북미 시장

제15장 남미 시장

제16장 중동 시장

제17장 아프리카 시장

제18장 경쟁 구도와 기업 프로파일

• 기업 프로파일
• Merck & Co. Inc
• Bristol Myers Squibb Company
• F. Hoffman-La Roche Ltd
• Johnson & Johnson
• AstraZeneca plc

제19장 기타 주요 기업 및 혁신 기업

• Novartis AG
• Pfizer Inc
• Eli Lilly and Company
• AbbVie
• Boehringer Ingelheim GmbH
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Amgen Inc
• Bayer AG
• Hikma Pharmaceuticals plc
• Fresenius SE & Co. KGaA
• Teva pharmaceutical Industries Ltd
• Ipsen SA
• Incyte Corp
• Aspen Pharmacare Holdings Limited

제20장 경쟁 벤치마킹

제21장 경쟁 대시보드

제22장 주요 인수합병(M&A)

• Novartis, Mariana Oncology 인수
• Johnson & Johnson(J& J), Ambrx Biopharma 인수
• Ipsen SA, Epizyme Inc 인수

제23장 항악성종양제 최근 동향

• 신장암과 유방암 치료의 진보
• 차세대 치료법은 악성 B 세포를 효과적으로 표적 치료
• 비인두암에 대한 혁신적인 면역종양요법
• 신규 리포좀 독소루비신 제제가 복수의 암종을 표적 치료

제24장 기회와 전략

• 항악성종양제 시장(2029년) : 새로운 기회를 제공하는 국가
• 항악성종양제 시장(2029년) : 새로운 기회를 제공하는 부문
• 항악성종양제 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제25장 항악성종양제 시장 : 결론과 제안

• 결론
• 권고
  • 제품
  • 장소
  • 가격
  • 프로모션
  • 인재

제26장 부록

영문목차

Anti-neoplastic agents refer to a broad class of pharmaceutical drugs that inhibit or prevent the growth and spread of tumors or malignant cells. These agents are primarily utilized by oncologists, hematologists, general practitioners and other healthcare professionals specializing in cancer treatment. Anti-neoplastic agents are administered throughout various stages of cancer management, from initial diagnosis and first-line therapy to advanced and metastatic disease treatment.

The anti-neoplastic agents market consists of sales by entities (organizations, sole traders and partnerships) of anti-neoplastic agents that are critical components in chemotherapy regimens, sometimes used in combination with surgery, radiation and targeted therapies to enhance treatment effectiveness.

The global anti-neoplastic agents market was valued at $91,811.97 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 7.00%.

Rise In Biologics Development

Rise in biologics development fueled the growth of the anti-neoplastic agents in the historic period. Anti-neoplastic agents are instrumental in driving the development of biologics, providing a foundational understanding of cancer treatment. They facilitate the integration of targeted biologic therapies, including monoclonal antibodies and immune checkpoint inhibitors, which deliver more precise, effective treatments with reduced side effects. By offering valuable insights into tumor biology and therapeutic pathways, these agents accelerate innovation in biologic therapies. For instance, according to the Pharmaceutical Research and Manufacturers of America (PhRMA), a US-based trade association, by the end of 2022, 40 biosimilars had received approval and 27 of them were available in the United States. Therefore, the rise in biologics development drove the growth of the anti-neoplastic agents market.

Enhancing Treatment Precision With Targeted Therapies

Major companies operating in the anti-neoplastic agents market are focusing on affordable drugs, such as generic cancer drugs and life-saving treatments, reduce healthcare costs and expand their market reach in price-sensitive regions. Generic cancer drugs are cost-effective alternatives to branded cancer medications that contain the same active ingredients, dosage and therapeutic effect, but are marketed under a different name and at a lower price once the original patent expires. For instance,n March 2024, Zydus Lifesciences, an India-based pharmaceutical company launched IBYRA, a generic version of the cancer drug Olaparib, in India. IBYRA, a next-generation PARP inhibitor, targets specific genetic mutations, particularly those related to homologous recombination deficiency (HRD), which are common in cancers like breast, ovarian, prostate and pancreatic cancers. This targeted therapy offers a more personalized and effective treatment approach, with Zydus partnering with MedGenome to provide homologous recombination deficiency (HRD) testing for patient identification.

The global anti-neoplastic agents market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up to 30.28% of the total market in 2024.

Anti-Neoplastic Agents Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global anti-neoplastic agents market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for anti-neoplastic agents? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The anti-neoplastic agents market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider anti-neoplastic agents market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by disease type and by end user.
• Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation- Contains the ma-rket values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by disease type and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
• Competitive Dashboard- Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
• Recent Developments- Information on recent developments in the market covered in the report.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for anti-neoplastic agents providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Type: Alkylating Agents; Antimetabolites; Hormones And Antagonists; Miscellaneous
• 2) By Disease Type: Gastrointestinal Cancer; Prostate Cancer; Lung Cancer; Breast Cancer; Other Disease Types
• 3) By End User: Hospitals; Clinics; Cancer Rehabilitation Centers; Ambulatory Surgical Centers; Other End Users
• Companies Mentioned: Merck & Co. Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Johnson & Johnson; AstraZeneca plc
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; anti-neoplastic agents indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Anti-Neoplastic Agents - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Anti-Neoplastic Agents Market Definition And Segmentations
• 6.4 Market Segmentation By Type
  • 6.4.1 Alkylating Agents
  • 6.4.2 Antimetabolites
  • 6.4.3 Hormones And Antagonists
  • 6.4.4 Miscellaneous
• 6.5 Market Segmentation By Disease Type
  • 6.5.1 Gastrointestinal Cancer
  • 6.5.2 Prostate Cancer
  • 6.5.3 Lung Cancer
  • 6.5.4 Breast Cancer
  • 6.5.5 Other Disease Types
• 6.6 Market Segmentation By End User
  • 6.6.1 Hospitals
  • 6.6.2 Clinics
  • 6.6.3 Cancer Rehabilitation Centers
  • 6.6.4 Ambulatory Surgical Centers
  • 6.6.5 Other End Users

7 Major Market Trends

• 7.1 Advancing Cancer Treatment Through Precision Medicine
• 7.2 Enhancing Treatment Precision With Targeted Therapies
• 7.3 Minimizing Toxicity Through Precision Oncology Approaches
• 7.4 Enhancing Cancer Outcomes Through Signal Pathway Inhibition

8 Anti-Neoplastic Agents Growth Analysis And Strategic Analysis Framework

• 8.1 Global Anti-Neoplastic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors)
  • 8.1.1 Political
  • 8.1.2 Economic
  • 8.1.3 Social
  • 8.1.4 Technological
  • 8.1.5 Environmental
  • 8.1.6 Legal
• 8.2 Analysis Of End User
  • 8.2.1 Hospitals
  • 8.2.2 Clinics
  • 8.2.3 Cancer Rehabilitation Centers
  • 8.2.4 Ambulatory Surgical Centers
• 8.3 Anti-Neoplastic Agents Market Growth Rate Analysis
• 8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 8.4.1 Market Drivers 2019 - 2024
  • 8.4.2 Market Restraints 2019- 2024
• 8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
• 8.6 Forecast Growth Contributors/Factors
  • 8.6.1 Quantitative Growth Contributors
  • 8.6.2 Drivers
  • 8.6.3 Restraints
• 8.7 Anti-Neoplastic Agents Total Addressable Market (TAM)

9 Anti-Neoplastic Agents Market Segmentation

• 9.1 Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.2 Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.3 Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.4 Anti-Neoplastic Agents Market, Sub-Segmentation By Alkylating Agents, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.5 Anti-Neoplastic Agents Market, Sub-Segmentation Of Antimetabolites, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.6 Anti-Neoplastic Agents Market, Sub-Segmentation By Hormones And Antagonists, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.7 Anti-Neoplastic Agents Market, Sub-Segmentation By Miscellaneous, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Anti-Neoplastic Agents Market, Regional and Country Analysis

• 10.1 Anti-Neoplastic Agents Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.2 Anti-Neoplastic Agents Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

• 11.1 Summary
• 11.2 Market Overview
  • 11.2.1 Region Information
  • 11.2.2 Market Information
  • 11.2.3 Background Information
  • 11.2.4 Government Initiatives
  • 11.2.5 Regulations
  • 11.2.6 Regulatory Bodies
  • 11.2.7 Major Associations
  • 11.2.8 Taxes Levied
  • 11.2.9 Corporate Tax Structure
  • 11.2.10 Investments
  • 11.2.11 Major Companies
• 11.3 Asia-Pacific Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.4 Asia-Pacific Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.5 Asia-Pacific Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.6 Asia-Pacific Anti-Neoplastic Agents Market: Country Analysis
• 11.7 China Market
• 11.8 Summary
• 11.9 Market Overview
  • 11.9.1 Country Information
  • 11.9.2 Market Information
  • 11.9.3 Background Information
  • 11.9.4 Government Initiatives
  • 11.9.5 Regulations
  • 11.9.6 Regulatory Bodies
  • 11.9.7 Major Associations
  • 11.9.8 Taxes Levied
  • 11.9.9 Corporate Tax Structure
  • 11.9.10 Investments
  • 11.9.11 Major Companies
• 11.10 China Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.11 China Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.12 China Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.13 India Market
• 11.14 India Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.15 India Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.16 India Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.17 Japan Market
• 11.18 Summary
• 11.19 Market Overview
  • 11.19.1 Country Information
  • 11.19.2 Market Information
  • 11.19.3 Background Information
  • 11.19.4 Government Initiatives
  • 11.19.5 Regulations
  • 11.19.6 Regulatory Bodies
  • 11.19.7 Major Associations
  • 11.19.8 Taxes Levied
  • 11.19.9 Corporate Tax Structure
  • 11.19.10 Investments
  • 11.19.11 Major Companies
• 11.20 Japan Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.21 Japan Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.22 Japan Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.23 Australia Market
• 11.24 Australia Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.25 Australia Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.26 Australia Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.27 Indonesia Market
• 11.28 Indonesia Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.29 Indonesia Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.30 Indonesia Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.31 South Korea Market
• 11.32 Summary
• 11.33 Market Overview
  • 11.33.1 Country Information
  • 11.33.2 Market Information
  • 11.33.3 Background Information
  • 11.33.4 Government Initiatives
  • 11.33.5 Regulations
  • 11.33.6 Regulatory Bodies
  • 11.33.7 Major Associations
  • 11.33.8 Taxes Levied
  • 11.33.9 Corporate Tax Structure
  • 11.33.10 Investments
  • 11.33.11 Major Companies
• 11.34 South Korea Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.35 South Korea Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.36 South Korea Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate tax structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Western Europe Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.4 Western Europe Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.5 Western Europe Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.6 Western Europe Anti-Neoplastic Agents Market: Country Analysis
• 12.7 UK Market
• 12.8 UK Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.9 UK Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.10 UK Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.11 Germany Market
• 12.12 Germany Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.13 Germany Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.14 Germany Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.15 France Market
• 12.16 France Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.17 France Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.18 France Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.19 Italy Market
• 12.20 Italy Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.21 Italy Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.22 Italy Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.23 Spain Market
• 12.24 Spain Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.25 Spain Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.26 Spain Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate Tax Structure
  • 13.2.10 Investments
  • 13.2.11 Major companies
• 13.3 Eastern Europe Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.4 Eastern Europe Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.5 Eastern Europe Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.6 Eastern Europe Anti-Neoplastic Agents Market: Country Analysis
• 13.7 Russia Market
• 13.8 Russia Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.9 Russia Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.10 Russia Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Government Initiatives
  • 14.2.5 Regulations
  • 14.2.6 Regulatory Bodies
  • 14.2.7 Major Associations
  • 14.2.8 Taxes Levied
  • 14.2.9 Corporate Tax Structure
  • 14.2.10 Investments
  • 14.2.11 Major Companies
• 14.3 North America Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.4 North America Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.5 North America Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.6 North America Anti-Neoplastic Agents Market: Country Analysis
• 14.7 USA Market
• 14.8 Summary
• 14.9 Market Overview
  • 14.9.1 Country Information
  • 14.9.2 Market Information
  • 14.9.3 Background Information
  • 14.9.4 Government Initiatives
  • 14.9.5 Regulations
  • 14.9.6 Regulatory Bodies
  • 14.9.7 Major Associations
  • 14.9.8 Taxes Levied
  • 14.9.9 Corporate Tax Structure
  • 14.9.10 Major Companies
• 14.10 USA Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.11 USA Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.12 USA Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.13 Canada Market
• 14.14 Summary
• 14.15 Market Overview
  • 14.15.1 Country Information
  • 14.15.2 Market Information
  • 14.15.3 Background Information
  • 14.15.4 Government Initiatives
  • 14.15.5 Regulations
  • 14.15.6 Regulatory Bodies
  • 14.15.7 Major Associations
  • 14.15.8 Taxes Levied
  • 14.15.9 Corporate Tax Structure
  • 14.15.10 Investments
  • 14.15.11 Major Companies
• 14.16 Canada Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.17 Canada Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.18 Canada Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Investments
  • 15.2.11 Major Companies
• 15.3 South America Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 South America Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 South America Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.6 South America Anti-Neoplastic Agents Market: Country Analysis
• 15.7 Brazil Market
• 15.8 Brazil Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.9 Brazil Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.10 Brazil Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Investments
  • 16.2.11 Major Companies
• 16.3 Middle East Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 Middle East Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 Middle East Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Investments
  • 17.2.11 Major Companies
• 17.3 Africa Anti-Neoplastic Agents Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Africa Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.5 Africa Anti-Neoplastic Agents Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

• 18.1 Company Profiles
• 18.2 Merck & Co., Inc
  • 18.2.1 Company Overview
  • 18.2.2 Products And Services
  • 18.2.3 Business Strategy
  • 18.2.4 Financial Overview
• 18.3 Bristol Myers Squibb Company
  • 18.3.1 Company Overview
  • 18.3.2 Products And Services
  • 18.3.3 Business Strategy
  • 18.3.4 Financial Overview
• 18.4 F. Hoffman-La Roche Ltd
  • 18.4.1 Company Overview
  • 18.4.2 Products And Services
  • 18.4.3 Business Strategy
  • 18.4.4 Financial Overview
• 18.5 Johnson & Johnson
  • 18.5.1 Company Overview
  • 18.5.2 Products And Services
  • 18.5.3 Business Strategy
  • 18.5.4 Financial Overview
• 18.6 AstraZeneca plc
  • 18.6.1 Company Overview
  • 18.6.2 Products And Services
  • 18.6.3 Business Strategy
  • 18.6.4 Financial Overview

19 Other Major And Innovative Companies

• 19.1 Novartis AG
  • 19.1.1 Company Overview
  • 19.1.2 Products And Services
• 19.2 Pfizer Inc
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
• 19.3 Eli Lilly and Company
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
• 19.4 AbbVie
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
• 19.5 Boehringer Ingelheim GmbH
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
• 19.6 Takeda Pharmaceutical Company Limited
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
• 19.7 Sanofi S.A.
  • 19.7.1 Company Overview
  • 19.7.2 Products And Services
• 19.8 Amgen Inc
  • 19.8.1 Company Overview
  • 19.8.2 Products And Services
• 19.9 Bayer AG
  • 19.9.1 Company Overview
  • 19.9.2 Products And Services
• 19.10 Hikma Pharmaceuticals plc
  • 19.10.1 Company Overview
  • 19.10.2 Products And Services
• 19.11 Fresenius SE & Co. KGaA
  • 19.11.1 Company Overview
  • 19.11.2 Products And Services
• 19.12 Teva pharmaceutical Industries Ltd
  • 19.12.1 Company Overview
  • 19.12.2 Products And Services
• 19.13 Ipsen SA
  • 19.13.1 Company Overview
  • 19.13.2 Products And Services
• 19.14 Incyte Corp
  • 19.14.1 Company Overview
  • 19.14.2 Products And Services
• 19.15 Aspen Pharmacare Holdings Limited
  • 19.15.1 Company Overview
  • 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

• 22.1 Novartis Acquired Mariana Oncology
• 22.2 Johnson & Johnson (J&J) Acquired Ambrx Biopharma
• 22.3 Ipsen SA Acquired Epizyme Inc

23 Recent Developments In Anti-neoplastic Agents

• 23.1 Therapeutic Advancement For Renal And Breast Cancer Care
• 23.2 Next-Generation Therapy Targets Malignant B Cells Effectively
• 23.3 Revolutionary Immuno-Oncology Therapy For Nasopharyngeal Carcinoma
• 23.4 Novel Liposomal Doxorubicin Formulation Targets Multiple Cancer Types

24 Opportunities And Strategies

• 24.1 Anti-Neoplastic Agents Market In 2029 - Countries Offering Most New Opportunities
• 24.2 Anti-Neoplastic Agents Market In 2029 - Segments Offering Most New Opportunities
• 24.3 Anti-Neoplastic Agents Market In 2029 - Growth Strategies
  • 24.3.1 Market Trend Based Strategies
  • 24.3.2 Competitor Strategies

25 Anti-Neoplastic Agents Market, Conclusions And Recommendations

• 25.1 Conclusions
• 25.2 Recommendations
  • 25.2.1 Product
  • 25.2.2 Place
  • 25.2.3 Price
  • 25.2.4 Promotion
  • 25.2.5 People

26 Appendix

• 26.1 Geographies Covered
• 26.2 Market Data Sources
• 26.3 Research Methodology
• 26.4 Currencies
• 26.5 The Business Research Company
• 26.6 Copyright and Disclaimer